Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Parenteral replenishment of fluid and calories in patients unable to take adequate oral intake,Correction of fluid and electrolyte imbalances,As a vehicle for intravenous drug administration
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Dextrose has a plasma half-life of approximately 1-2 hours; sodium and chloride have half-lives that depend on renal function and hydration status, typically 6-12 hours for sodium. In clinical context, half-life is not typically used for fluid and electrolyte replacement.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the citric acid cycle; sodium chloride is not metabolized.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Dextrose and sodium chloride are endogenous substances. Dextrose is metabolized to CO2 and water; excess is excreted renally as glucose. Sodium and chloride are primarily excreted renally, with minimal biliary/fecal elimination. Nearly 100% of infused sodium and chloride are eliminated renally under normal conditions.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: negligible (<1%). Sodium: negligible. Chloride: negligible.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose: approximately 0.2 L/kg (extracellular fluid). Sodium: 0.2 L/kg (extracellular fluid). Chloride: 0.2 L/kg (extracellular fluid). These reflect distribution primarily in extracellular space.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
e GFR <30 m L/min: Use with caution; monitor fluid and electrolyte balance; adjust volume and rate based on renal function and urine output.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment required; use caution in severe hepatic impairment due to potential volume overload.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based: Initial dose 5-10 m L/kg, may repeat as needed; maintenance: 80-120 m L/kg/day for infants and 60-80 m L/kg/day for older children; adjust rate based on clinical response and glucose/electrolyte monitoring.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Start at lower end of adult dose; monitor for fluid overload, hyperglycemia, and electrolyte disturbances due to decreased renal function and cardiovascular reserve.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Risk of hyperglycemia, especially in patients with diabetes mellitus or impaired glucose tolerance,Risk of fluid overload, particularly in patients with cardiac or renal impairment,Electrolyte imbalances with prolonged use or rapid infusion,May cause phlebitis or extravasation at infusion site,Use with caution in patients with intracranial or intraspinal hemorrhage
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia (severe) or diabetic coma with hyperglycemia,Hypersensitivity to any component,Clinically significant hypernatremia or fluid overload,Patients with increased intracranial pressure
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. However, due to dextrose content, patients with diabetes should monitor blood glucose closely. Avoid concurrent use with alcohol due to risk of hypoglycemia or hyperglycemia.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of large volumes may cause electrolyte imbalances and fluid overload, potentially affecting fetal hydration status.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Both dextrose and sodium chloride are endogenous substances and are present in breast milk at concentrations similar to maternal plasma. M/P ratio: Not applicable; considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustments required for standard maintenance fluids. However, pregnant patients may have increased volume of distribution and renal clearance; monitor for fluid and electrolyte balance, and adjust infusion rate accordingly to prevent overload.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Contains 10% dextrose (100 g/L) and 0.2% sodium chloride (34 m Eq/L Na+ and Cl-). Osmolality approximately 505 m Osm/L, p H ~4.0. Provides 340 kcal/L. Use with caution in patients with fluid overload, heart failure, or renal impairment. Monitor serum glucose, electrolytes, and fluid balance. Not for use as a sole source of nutrition; consider thiamine supplementation in chronic alcoholics to prevent Wernicke's encephalopathy. Do not administer with blood products through same IV line.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This solution provides sugar (dextrose) and salt (sodium chloride) to help maintain your body's fluid and energy balance.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing, during infusion.,Inform your healthcare provider if you have diabetes, high blood pressure, heart failure, or kidney disease.,This solution is given through a vein; you may feel warmth or discomfort at the injection site.,Follow your doctor's instructions regarding fluid intake and monitoring of blood sugar levels.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.